A Phase 1 Open-Label Study Of Pf-00299804 In Healthy Volunteers To Demonstrate The Bioequivalence Of The Proposed Commercializable Formulation Administered As One 45-Mg Tablet Relative To Three 15-Mg Clinical Formulation Tablets.
Phase of Trial: Phase I
Latest Information Update: 27 Jun 2011
At a glance
- Drugs Dacomitinib (Primary)
- Indications Cancer
- Focus Pharmacokinetics
- 27 Jun 2011 Actual end date (May 2011) added as reported by ClinicalTrials.gov.
- 27 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 03 Jun 2011 Planned end date changed from 1 May 2011 to 1 Jun 2011 as reported by ClinicalTrials.gov.